AstraZeneca PLC (Mexico) Performance
| AZNN Stock | MXN 1,384 6.50 0.47% |
The firm shows a Beta (market volatility) of -0.39, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning AstraZeneca PLC are expected to decrease at a much lower rate. During the bear market, AstraZeneca PLC is likely to outperform the market. At this point, AstraZeneca PLC has a negative expected return of -0.35%. Please make sure to confirm AstraZeneca PLC's total risk alpha, potential upside, kurtosis, as well as the relationship between the treynor ratio and skewness , to decide if AstraZeneca PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AstraZeneca PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 6 B | |
| Free Cash Flow | 7.2 B |
AstraZeneca |
AstraZeneca PLC Relative Risk vs. Return Landscape
If you would invest 175,139 in AstraZeneca PLC on September 2, 2024 and sell it today you would lose (36,789) from holding AstraZeneca PLC or give up 21.01% of portfolio value over 90 days. AstraZeneca PLC is generating negative expected returns and assumes 2.413% volatility on return distribution over the 90 days horizon. Simply put, 21% of stocks are less volatile than AstraZeneca, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
AstraZeneca PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AstraZeneca PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AstraZeneca PLC, and traders can use it to determine the average amount a AstraZeneca PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.145
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AZNN |
Estimated Market Risk
| 2.41 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AstraZeneca PLC is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AstraZeneca PLC by adding AstraZeneca PLC to a well-diversified portfolio.
AstraZeneca PLC Fundamentals Growth
AstraZeneca Stock prices reflect investors' perceptions of the future prospects and financial health of AstraZeneca PLC, and AstraZeneca PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AstraZeneca Stock performance.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 4.74 T | |||
| Shares Outstanding | 3.1 B | |||
| Price To Earning | 39.41 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 95.42 X | |||
| Revenue | 44.35 B | |||
| EBITDA | 9.33 B | |||
| Cash And Equivalents | 15.63 B | |||
| Cash Per Share | 5.96 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 1.90 % | |||
| Book Value Per Share | 11.96 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 19.72 X | |||
| Total Asset | 96.48 B | |||
| Retained Earnings | 8.07 B | |||
| Current Asset | 12.77 B | |||
| Current Liabilities | 15.93 B | |||
About AstraZeneca PLC Performance
Evaluating AstraZeneca PLC's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if AstraZeneca PLC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AstraZeneca PLC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 76100 people.Things to note about AstraZeneca PLC performance evaluation
Checking the ongoing alerts about AstraZeneca PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AstraZeneca PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AstraZeneca PLC generated a negative expected return over the last 90 days |
- Analyzing AstraZeneca PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AstraZeneca PLC's stock is overvalued or undervalued compared to its peers.
- Examining AstraZeneca PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AstraZeneca PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AstraZeneca PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AstraZeneca PLC's stock. These opinions can provide insight into AstraZeneca PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.